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ABSTRACT

Objective: To examine moderators and predictors of response to behavior therapy for tics in children and adults with Tourette syndrome and chronic tic disorders.

Methods: Data from 2 10-week, multisite studies (1 in children and 1 in adults; total n 5 248)
comparing comprehensive behavioral intervention for tics (CBIT) to psychoeducation and supportive therapy (PST) were combined for moderator analyses. Participants (177 male, 71 female)
had a mean age of 21.5 6 13.9 years (range 9–69). Demographic and clinical characteristics,
baseline tic-suppressing medication, and co-occurring psychiatric disorders were tested as
potential moderators for CBIT vs PST or predictors of outcome regardless of treatment assignment. Main outcomes measures were the Yale Global Tic Severity Scale Total Tic score and the
Clinical Global Impression–Improvement score assessed by masked evaluators.

Results: The presence of tic medication significantly moderated response to CBIT vs PST (p 5
0.01). Participants showed tic reduction after CBIT regardless of tic medication status, but only
participants receiving tic medication showed reduction of tics after PST. Co-occurring psychiatric
disorders, age, sex, family functioning, tic characteristics, and treatment expectancy did not
moderate response. Across both treatments, greater tic severity (p 5 0.005) and positive participant expectancy (p 5 0.01) predicted greater tic improvement. Anxiety disorders (p 5 0.042)
and premonitory urge severity (p 5 0.005) predicted lower tic reduction.
Conclusions: Presence of co-occurring attention-deficit/hyperactivity disorder, obsessivecompulsive disorder, or anxiety disorders did not moderate response to CBIT. Although participants on tic medication showed improvement after CBIT, the difference between CBIT and
PST was greater for participants who were not on tic-suppressing medication.

ClinicalTrials.gov identifiers: The child and adult CBIT studies are listed on clinical trials.gov
(NCT00218777 and NCT00231985, respectively).
Classification of evidence: This study provides Class I evidence that CBIT is effective in reducing
tic severity across subgroups of patients with chronic tic disorders, although the difference
between treatments was smaller for participants on tic-suppressing medications, suggesting
reduced efficacy in this subgroup. Neurology® 2017;88:1029–1036
GLOSSARY
ADHD 5 attention-deficit/hyperactivity disorder; ADHD-RS 5 Attention Deficit Hyperactivity Disorder Rating Scale;
BFAM 5 Brief Family Assessment Measure III; CBIT 5 Comprehensive Behavioral Intervention for Tics; CGI-I 5 Clinical
Global Impression–Improvement; CGI-S 5 Clinical Global Impression–Severity; CTD 5 chronic tic disorder; LSM 5 least
squares means; OCD 5 obsessive-compulsive disorder; PST 5 psychoeducation and supportive therapy; TS 5 Tourette
syndrome; YGTSS 5 Yale Global Tic Severity Scale.

Chronic tic disorders (CTDs)—Tourette syndrome (TS) and chronic motor or vocal tic
disorder—are characterized by childhood onset of motor or vocal tics affecting an estimated
14/1,000 children.1 Tics usually begin between 5 and 7 years of age and reach peak severity
between 9 and 12 years, with gradual improvement through adolescence; a minority of
patients have moderate to severe tics into adulthood.2 CTDs often co-occur with other
From Yale University School of Medicine (D.G.S., L.K., J.D.), New Haven, CT; Marquette University (D.W.W.), Milwaukee, WI; University of
California at Los Angeles Geffen School of Medicine (J.P.); Massachusetts General Hospital/Harvard Medical School (S.W.), Boston; University of
Texas Health Science Center at San Antonio (A.L.P.); Weill Cornell Medical College (J.T.W.), New York, NY; and Marcus Autism Center (L.S.),
Emory University School of Medicine, Atlanta, GA.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
© 2017 American Academy of Neurology
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Table 1

Demographic and clinical characteristics of participants in CBIT trials
by treatment group (n 5 248)

Mean age, y (SD)

CBIT
(n 5 124)

PST
(n 5 124)

21.8 (13.9)

21.2 (13.9)

20 (16.1)

21 (16.9)

Study site, n (%)
Johns Hopkins University
University of California, Los Angeles

21 (16.9)

24 (19.4)

University of Wisconsin–Milwaukee

20 (16.1)

20 (16.1)

Massachusetts General Hospital

24 (19.4)

23 (18.5)

University of Texas Health
Science Center

21 (16.9)

19 (15.3)

Yale University

18 (14.5)

17 (13.7)

Male

84 (67.7)

93 (75.0)

Female

40 (32.3)

31 (25.0)

White, non-Hispanic

99 (79.8)

106 (85.5)

White, Hispanic

17 (13.7)

9 (7.3)

Sex

Race

Black

1 (0.8)

4 (3.2)

Asian/Pacific Islander

6 (4.8)

3 (2.4)

Other

1 (0.8)

2 (1.6)

108.3 (13.0)

108.2 (13.6)

Tourette syndrome

111 (89.5)

110 (88.7)

Chronic motor tic disorder

11 (8.9)

14 (11.3)

Chronic vocal tic disorder

2 (1.6)

0

No co-occurring disorders

45 (35.7)

51 (41.8)

Attention-deficit/hyperactivity
disorder

37 (29.8)

30 (24.2)

Obsessive-compulsive disorder

21 (16.9)

25 (20.2)

Anxiety disordera

35 (28.2)

38 (30.6)

Otherb

24 (19.4)

23 (18.5)

Mean IQ (SD)

psychiatric disorders, including attentiondeficit/hyperactivity disorder (ADHD),
obsessive-compulsive disorder (OCD), and
other anxiety and mood disorders.3–5
Available treatments for CTDs focus on tic
reduction or a co-occurring condition.
Medications to reduce tic severity include
dopamine receptor blocking agents (e.g., haloperidol and risperidone) and a2-adrenergic
agonists (e.g., clonidine and guanfacine).6,7
Efficacy of Comprehensive Behavioral Intervention for Tics (CBIT)8 for reducing tic
severity was demonstrated in 2 large,
10-week randomized controlled trials of
youth (n 5 126)9 and adults (n 5 122).10
In both trials, CBIT was compared to psychoeducation and supportive therapy (PST).
Given that the CBIT studies used the same
design and outcome measures, we combined
these datasets to identify baseline characteristics that differentially affected response
to CBIT vs PST (moderators) or affected
outcome equally across both treatments
(predictors).11

Diagnoses

Co-occurring diagnoses

Medication status
No medication

84 (67.7)

87 (70.2)

On tic medication

40 (32.3)

37 (29.8)

Antipsychoticc

13 (10.5)

9 (7.3)

d

a-Agonist

17 (13.7)

18 (14.5)

Anticonvulsante

1 (0.8)

3 (2.4)

Benzodiazepinef

2 (1.6)

1 (0.8)

a-Agonist and antipsychotic

5 (4.0)

2 (1.6)

Antipsychotic and
anticonvulsant

1 (0.8)

1 (0.8)

a-Agonist and anticonvulsant

0

1 (0.8)

Antipsychotic and
benzodiazepine

0

1 (0.8)

Continued
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METHODS Primary research question. The primary
research question was to examine moderators and predictors of
response to behavior therapy for tics in children and adults with
CTDs. This study provides Class I evidence.

Design. Participants were randomized (1:1) to CBIT or PST.
The random assignment was within-site and stratified by the
presence of tic medication.
Participants. Children, adolescents, and adults with diagnosis
of TS or CTD with a Clinical Global Impression of Severity
(CGI-S)12 score of moderate (4) or greater were eligible to
participate. Those with TS were required to have a Yale Global
Tic Severity Scale (YGTSS)13 Total Tic score of $13 in the
child study and $14 in the adult study. For participants with
CTD only, the YGTSS total motor or vocal tic scores had to be
$9 and $10 in the child and adult studies, respectively. Participants on psychotropic medication (including tic medication) were eligible if the medication was stable for at least 6
weeks before baseline with no planned changes during the 10week trial. Individuals with IQ ,80, current diagnosis of
substance abuse or substance dependence, lifetime diagnosis
of autism spectrum disorder or psychotic disorder, or
previous treatment with 4 or more sessions of habit reversal
training for tics were excluded. Those with co-occurring
diagnoses (e.g., depression, anxiety, OCD, or ADHD) were
eligible if the condition did not require immediate treatment
or change in existing treatment.9,10
Three sites enrolled participants in the child study (Johns
Hopkins University, University of California at Los Angeles, University of Wisconsin–Milwaukee) and 3 sites enrolled older
adolescent and adult participants (Massachusetts General Hospital/Harvard Medical School, Health Sciences Center University
of Texas at San Antonio, Yale University).
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Table 1

assignment, administered the YGTSS and CGI-I at baseline,
midpoint (week 5), and endpoint (week 10).

Continued
CBIT
(n 5 124)

PST
(n 5 124)

Antipsychotic and donepezil

0

1 (0.8)

Other

1 (0.8)

0

Abbreviations: CBIT 5 Comprehensive Behavioral Intervention for Tics; PST 5 psychoeducation and supportive therapy.
a
Generalized anxiety, social anxiety, separation anxiety, specific phobia, panic, and posttraumatic stress disorder.
b
Major depression, substance use disorder, bipolar disorder, eating disorder, and
trichotillomania.
c
Haloperidol, pimozide, risperidone, aripiprazole, olanzapine, and fluphenazine.
d
a-Agonists: guanfacine, clonidine.
e
Anticonvulsants: valproate, levetiracetam, topiramate.
f
Clonazepam.

Standard protocol approvals, registrations, and patient
consents. The studies were approved by the institutional review
boards at each site. Adult participants and parents of child participants provided consent; children provided assent.
The child and adult CBIT studies are listed on clinical trials.
gov (NCT00218777 and NCT00231985, respectively).

Treatments. CBIT and PST consisted of 8 individually delivered 60- to 90-minute sessions administered over 10 weeks.
Caretakers of children and significant others of adults were
invited to participate. CBIT provides education about tic
disorders and relaxation training and teaches patients to inhibit
tics with a competing motor movement. CBIT also addresses
situational antecedents and consequences of tics as contextual
factors that may inadvertently occasion or reinforce tics. PST
provided developmentally relevant information about CTDs
and controlled for time and therapist attention, but did not
include tic management strategies. Therapists with at least
a master’s degree were trained to reliability on both treatments
and received weekly supervision at each site. Sessions were
recorded on video and a 13%–16% randomly selected set of
therapy sessions was independently reviewed for fidelity.9,10
Procedures. Developmentally appropriate structured diagnostic
interviews assessed for psychiatric diagnoses. The Anxiety Disorders Interview Schedule for DSM-IV: Child Version14
supplemented with a tic disorders module was administered
separately to parents and youths in the child study. The
Structured Clinical Interview for DSM-IV15 with tic disorder
and adult ADHD modules was used in the adult trial.
Symptom severity of ADHD was assessed with parent ratings
and self-reports of the Attention Deficit Hyperactivity Disorder
Rating Scale (ADHD-RS).16 Full-scale IQ was assessed by the
Wechsler Abbreviated Scale of Intelligence17 in children and by
the Wechsler Test of Adult Reading18 in adults. An experienced
clinician at each site confirmed the presence and stability of tic
medication.

Outcome measures. The YGTSS13 is a semi-structured
interview that measures tic severity over the prior week. Motor
and phonic tics are separately rated on a 0–5 scale for number,
frequency, intensity, complexity, and interference. The YGTSS
Total Tic score was the first primary outcome measure. The
second primary outcome measure was the Clinical Global
Impression–Improvement (CGI-I)12 with scores ranging from
very much improved (1) to very much worse (7); scores of much
improved (1) or very much improved (2) defined positive
response. Trained raters, who were blind to treatment

Moderator and predictor variables. We selected baseline
characteristics as moderators that could influence differential
response to CBIT vs PST based on studies of behavioral interventions for other neurodevelopmental disorders19–21 and on consensus of CBIT investigators. The same variables were examined as
predictors, which are characteristics affecting response regardless
of treatment assignment.22 Selected variables included presence of
baseline tic medication, tic phenomenology (age at onset, current
severity, complexity, and premonitory urges), age, sex, family
functioning, treatment expectancy, and co-occurring ADHD,
OCD, and anxiety disorders.
Tic medication. Seventy-seven (31%) participants reported
taking 1 or more tic medications: 32 antipsychotics, 44 a2 agonists, 5 mood stabilizers, and 4 benzodiazepines. Tic medication
status was initially coded 0 (on a medication) or 1 (no tic medication). To test the effects of the most common tic medications in
this sample, we created a 4-level variable: 1 5 no tic medications,
2 5 antipsychotics only, 3 5 a2 agonists only, and 4 5 both.
Tic phenomenology. We considered age at onset, tic complexity (cutoff greater than 3 on the YGTSS complexity item),23
overall severity (CGI-S of moderate vs marked or greater), and
premonitory urge based on the 9-item self-report Premonitory
Urges for Tics Scale.24
Demographic and family characteristics. Age was examined
as a continuous variable. In addition, we dichotomized age into
9–15 years and $16 years. This division reflects the replicated
observation that tics tend to decline throughout adolescence.
Thus, study participants age 16 years and older may have a more
persistent form of CTDs. Family functioning was measured by
the Brief Family Assessment Measure III (BFAM),25 which reflects family communication, problem-solving, and affective
expression. The BFAM was completed by caregivers and participants in the child study and by adult participants. A z score was
created based on the average of child and parent BFAM scores
and the raw scores from adult participants.
Treatment expectations. After the first CBIT or PST session,
we collected a 3-item questionnaire from participants, parents, and
therapists in the child study and from participants and therapists in
the adult study. Items such as “I expect to get control over my tics
though this treatment” were rated on a scale from 1 5 strongly
disagree to 5 5 strongly agree. Thus, higher scores indicated
greater expectancy for treatment benefits. z Scores were derived
from the average of child and parent ratings in the child study and
self-reports in the adult study and then merged. We also created a z
score for therapist treatment expectation across both trials.
Data analysis. The effect of treatment on the YGTSS Total
Tic score was tested with mixed-model repeated-measures
analyses, adjusted for baseline scores.26 These analyses were
conducted on the modified intention-to-treat population (all
participants with at least 1 postrandomization assessment visit
[n 5 232]). The model included fixed effects for treatment (2
levels), time (5 and 10 weeks), site (6 sites), interaction of
treatment with time, a random effect for participant, and 3and 2-way interactions of time, treatment, and moderator
variable. Treatment-by-site interactions were not significant
for any of the outcome variables and were excluded from the
models. Three-way interactions (treatment 3 time 3
moderator) were not significant and were dropped from all
models. In the absence of any significant 3-way interactions,
we examined 2-way interactions (moderator 3 treatment) on
the assumption that treatment differences between levels of the
Neurology 88
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Figure

Moderating effects of tic medication on Yale Global Tic Severity Scale
(YGTSS) Total Tic score

RESULTS The combined sample included 177 male
and 71 female participants (n 5 248), mean (SD) age
21.5 (613.9) years, range 9–69 years. There were no
significant group differences on any demographic or
clinical variables (table 1). Additional characteristics
of the child and adult participants have been reported
elsewhere.9,10,23,27

Moderation. The presence of tic medication significantly moderated response to CBIT, favoring those
on no tic medication (F1,222 5 7.07, p 5 0.01) (figure). The 4-level tic medication variable (no tic
medication, antipsychotics only, a2 agonists only,
or both) also significantly moderated treatment
response (F3,210 5 3.26, p 5 0.023) (table 2).
Table 3 shows least squares means (LSM) and SD
for participants receiving and not receiving

Table 2

Baseline characteristics examined as
potential moderators of treatment
response (n 5 248)
Test
F

Category and variable

p

Concomitant tic medication
Any tic medication (dichotomous variable)

7.07 0.01

Antipsychotics; a-agonists; both; or no
medications (4 groups)

3.26 0.02

Co-occurring disorders
ADHD

0.13 0.72

Severity of ADHD symptoms

0.05 0.95

OCD

0.00 0.98
a

Any anxiety disorder

1.06 0.30

Tic phenomenology

(A) Change from baseline in participants on any tic-suppressing medication (n 5 77) to those
not on tic medication. (B, C) Change in YGTSS in participants receiving a2 agonists only (n 5
37) and antipsychotic medication only (n 5 25). Error bars represent standard errors. CBIT 5
Comprehensive Behavioral Intervention for Tics; PST 5 psychoeducation and supportive
therapy.

moderator were the same at weeks 5 and 10. To identify
predictors of change on the YGTSS Total Tic score, we
checked for significant main effects for baseline
characteristics regardless of treatment assignment.22 Given
the exploratory nature of these moderator and predictor
analyses, we did not correct for multiple comparisons.26
Dichotomously coded moderator variables were entered in
the mixed model repeated-measures analysis with adjustment
for baseline YGTSS scores. Continuous variables were centered
prior to analysis by subtracting the variable mean from the individual scores. Baseline and endpoint adjusted least squares means
and SD for the YGTSS Total Tic score for the CBIT and PST
groups stratified by the moderator variables are presented. Effect
sizes were calculated by subtracting the change in YGTSS scores
in PST from the change in the CBIT divided by the SD for the
full sample at baseline.
1032
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Age at onset, y

0.04 0.84

Presence of complex tics

1.58 0.21

Tic severity (moderate vs severe on
CGI-S)a

1.36 0.24

Severity of premonitory urgesa

0.68 0.41

Demographic and clinical characteristics
Age (continuous variable)

0.06 0.81

Age (2 groups: 9–15 and 16 and older)

0.11 0.74

Sex

1.51 0.22

Family functioning
Mean family assessment measure score

1.53 0.22

Treatment expectancy
Participant pretreatment expectancya

0.36 0.55

Therapist pretreatment expectancy

0.46 0.50

Abbreviations: ADHD 5 attention-deficit/hyperactivity disorder; CGI-S 5 Clinical Global Impression–Severity; OCD 5
obsessive-compulsive disorder.
a
Predictors with significant main effect (i.e., baseline
characteristics that predicted change in tics regardless of
treatment that the person has received).
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Table 3

Least squares means (SD) Yale Global Tic Severity Scale Total Tic
scores by treatment group stratified by tic medication, presence of
ADHD, OCD, and anxiety disorders, and by moderate vs severe tics
CBIT

PST

Baseline

Week 10

Baseline

Week 10

Effect size

Not on tic medication

23.7 (5.9)

16.4 (8.8)

22.5 (6.3)

21.6 (6.1)

1.02

On any tic medication

25.1 (6.9)

18.7 (4.1)

24.5 (6.2)

19.8 (6.2)

0.27

On a2 agonists

26.1 (6.1)

19.6 (5.9)

24.0 (6.0)

17.9 (6.3)

0.07

On antipsychotics

25.6 (7.7)

17.1 (6.5)

24.4 (4.6)

20.8 (6.5)

0.77

No ADHD

24.0 (5.8)

17.1 (6.1)

22.9 (6.0)

21.2 (3.5)

0.83

ADHD

24.4 (7.2)

17.3 (6.1)

23.6 (7.3)

20.5 (11.4)

0.64

No OCD

23.9 (6.2)

17.1 (6.1)

22.8 (6.5)

20.9 (6.2)

0.78

OCD

25.0 (6.5)

17.3 (5.9)

24.4 (5.5)

21.9 (6.1)

0.82

No anxiety

23.8 (6.3)

17.1 (5.9)

23.3 (6.9)

20.5 (6.2)

0.62

25.0 (6.2)

17.4 (6.2)

22.6 (4.7)

22.4 (6.0)

1.17

Moderate tics

21.7 (4.9)

16.7 (6.2)

20.9 (5.4)

20.1 (6.1)

0.93

Marked/severe ticsa

28.9 (5.9)

18.0 (6.1)

26.8 (6.0)

23.0 (6.4)

1.18

Any anxiety diagnosis
a

Abbreviations: ADHD 5 attention-deficit/hyperactivity disorder; CBIT 5 Comprehensive
Behavioral Intervention for Tics; OCD 5 obsessive-compulsive disorder; PST 5 psychoeducation and supportive therapy.
a
As measured on Clinical Global Impression–Severity.

medication by the treatment condition. Using LSM,
the treatment comparison at week 10 in the CBIT
condition for participants receiving vs not receiving
medication was statistically significant (t 5 2.09, p 5

Table 4

Rates of positive response on Clinical Global Impression–Improvement
scale by tic medication status in combined sample (n 5 248)
Positive
Negative
response, n (%) response, n (%) Test, p value

Unadjusted
odds ratio

Overall
CBIT

56 (45.2)

68 (54.8)

PST

16 (12.9)

108 (87.1)

CBIT

43 (51.2)

41 (48.8)

PST

10 (11.5)

77 (88.5)

x2 5 29.77, p , 0.0001 5.56

Not on tic
medication

x2 5 31.49, p , 0.0001 8.07

On any tic
medication
CBIT

13 (32.5)

27 (67.5)

PST

6 (16.2)

31 (83.8)

CBIT

8 (47.1)

9 (52.9)

PST

5 (25.0)

15 (75.0)

x2 5 2.74, p 5 0.098

2.49

On a2 agonists

Predictors. There were no significant main effects on
Fisher exact, p 5 0.188

2.66

Fisher exact, p 5 0.604

2.73

On
antipsychotics
CBIT

3 (21.4)

11 (78.6)

PST

1 (9.1)

10 (90.9)

0.04). For participants on a2 agonists, the
comparison of week 10 LSM revealed no difference
between CBIT and PST (t 5 0.82, p 5 0.41). In
contrast, participants in the PST condition who were
receiving a2 agonists showed significantly greater tic
reduction that participants not on tic medication (t 5
22.37, p 5 0.019).
The presence of ADHD did not moderate treatment effect in participants ,18 years old (n 5 152)
(F1,132 5 0.01, p 5 0.94) or in the combined child
and adult samples (n 5 248, F1,222 5 0.13, p 5 0.72).
Moderating effects of ADHD symptom severity tested
using ADHD-RS z scores were not significant in children and adults separately or in the combined sample
(F1,219 5 0.79, p 5 0.38). The presence of OCD or
any anxiety disorder exclusive of OCD did not moderate treatment response (F1,222 5 0.01, p 5 0.1 and
F1,222 5 1.06, p 5 0.30, respectively).
There were no significant treatment interactions
with age at onset, presence of complex tics, tic severity
on the CGI-S, the severity of premonitory urges, sex,
BFAM, participant, or therapist expectancy (table 2).
Baseline age (centered variable), as a continuous variable or when dichotomized into younger and older
age groups, did not moderate outcome.
The effect size for CBIT vs PST was 1.02 for
participants not on tic medication compared to
0.27 for those on tic medication. To evaluate further the moderating effects of tic medication, we
compared participants on no tic medication, antipsychotics only, a2 agonists only, or both (table 3
and figure). Participants on a2 agonists (CBIT n 5
17; PST n 5 20) showed similar improvement in
both groups (t 5 0.82, p 5 0.41; effect size 5
0.07). By contrast, for participants on antipsychotic
medication (CBIT n 5 14; PST n 5 11), the treatment difference was only slightly lower than the
treatment difference for participants not on tic
medication (t 5 1.39, p 5 0.16; effect size 5
0.77). Table 4 shows the overall rate of positive
response on the CGI-I and by tic medication status.
For participants on no tic medication, the rate of
positive response in CBIT was significantly greater
than for PST. For participants on a tic medication,
the response rate for CBIT was twice that for PST,
but this difference was not significant.

Abbreviations: CBIT 5 Comprehensive Behavioral Intervention for Tics; PST 5 psychoeducation and supportive therapy.

age at onset, presence of complex tics, sex, or family
functioning. Greater overall severity at baseline as
measured on the CGI-S predicted a greater
reduction of tics regardless of treatment condition
(F1,222 5 8.22, p 5 0.005). Greater severity of
premonitory urges at baseline predicted lesser tic
reduction in both treatments (F1,225 5 8.13, p 5
0.005). Positive expectancy by participants was
Neurology 88
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a significant predictor of treatment benefit (F1,210 5
6.72, p 5 0.01). Anxiety disorders (exclusive of
OCD) predicted lower tic reduction at week 10
regardless of treatment condition (F1,222 5 4.17,
p 5 0.042). Otherwise co-occurring psychiatric
disorders did not predict treatment outcome.
DISCUSSION Data from the child and adult CBIT vs
PST trials (n 5 248) were combined to examine
moderators and predictors of treatment response.
Compared to participants on tic medication, the
treatment effect of CBIT was significantly larger in
participants on no tic medication. This differential
response was evident in the YGTSS Total Tic score
and the rate of positive response on the CGI-I scored
by a blinded evaluator. The presence of a lifetime
diagnosis of ADHD, OCD, or other anxiety
disorders did not moderate treatment response to
CBIT, nor did age, sex, current severity of ADHD
symptoms, tic severity, or severity of premonitory
urges.
The moderating effect of tic-suppressing medication warrants closer inspection. First, the use of
tic-suppressing medication may indicate greater tic
severity. At baseline, there was no difference in
YGTSS Total Tic scores in participants on tic medication compared to those not taking a tic medication.
However, because the premedication tic severity for
those on tic medication is unknown, the role of tic
severity in these analyses is unclear.
Second, of the 248 participants, only 77 (31%)
were on a tic-suppressing medication (primarily antipsychotics or a2 agonists). As shown in table 3, the
difference in YGTSS change scores between CBIT
and PST was 1.7 points for participants on any tic
medication compared to a difference of 6.4 points for
participants not on tic medication (effect sizes 0.27
and 1.02, respectively). Although the numbers are
small, there were differences by drug class. The
CBIT-PST YGTSS change-score difference for participants on antipsychotic medications was 4.9 points
(effect size 0.77), which was similar to the improvement in participants on no tic medication. By contrast, for participants on a2 agonists, the difference in
YGTSS change scores between treatments was 0.4
points (effect size 0.07). This attenuated effect size
was largely due to the 6.1-point improvement in the
YGTSS in the PST group on a2 agonists compared
to a 6.5-point reduction in CBIT. When examined
categorically on the CGI-I, participants on no tic
medication showed a higher positive response rate
than those on tic medication with no apparent difference by drug class.
Although participants not on tic medication
showed greater magnitude of benefit and likelihood
of positive response, participants on tic medication
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also showed improvement with CBIT. Thus, within
the CBIT group, there was a 7.3-point reduction in
the YGTSS Total Tic score in participants not on
tic-suppressing medication. This is remarkably
similar to the 6.5-point reduction for CBIT in participants receiving a2 agonists for tics and the 8.5-point
reduction in participants on antipsychotics for tics.
The 6.1-point decrease in tic severity in the PST
group on a2 agonists for tics reduced the treatment
difference between CBIT and PST for all participants
on tic medication and may explain the significant
interaction. The smaller CBIT-PST treatment difference in participants on a2 agonists need not imply
that patients on a2 agonists should not be offered
CBIT.
The predictor analysis identified 4 variables that
affected outcome regardless of treatment assignment:
co-occurring anxiety disorders, severity of premonitory urges, participant positive expectancy, and higher
overall severity as measured on the CGI-S. Participants with a co-occurring anxiety disorder showed
less tic reduction after 10 weeks. Although CBIT includes brief relaxation training, incorporation of more
active anxiety and stress management strategies in
CBIT may be useful. The severity of premonitory
urges was also associated with lower tic reduction.
Despite the deliberate teaching on early detection of
the urge and initiation of voluntary competing
response in CBIT, premonitory urges did not
improve with CBIT.9,10 The current analysis suggests
that the severity of premonitory urges impeded
improvement in both study treatments. Greater levels
of premonitory urges may be associated with more
treatment-resistant forms of CTDs.28
Positive expectancy for change among study participants and parents was associated with greater tic
reduction over time. This nonspecific effect suggests
that some participants and their parents were optimistic that therapeutic attention to the problem of
chronic tics could be beneficial.29 When overall severity was dichotomized on CGI-S of moderate vs
marked or greater, participants with greater overall
severity also showed greater tic reduction over time
regardless of treatment condition.
Positive expectations for treatment depend, at least
in part, on agreement between the patient and the clinician on the goals of treatment as well as the specific
components of the therapy.30 Thus, open discussion
about the goal (tic reduction) and techniques of
CBIT (e.g., awareness training and competing
response training) between the therapist and the
patient is warranted.
These results should be considered in light of limitations. First, the CBIT studies were designed to test
main effects. By definition, moderator and predictor
analyses are exploratory. Second, although the effect
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size and likelihood of positive response were lower for
participants on tic medication, the subgroups by
medication class were small, making it difficult to
interpret the findings.
CBIT is helpful for reducing tics in children and
adults regardless of coexisting tic medication treatment, although the difference between CBIT and
PST was smaller for participants on tic-suppressing
medications. PST was designed to include psychoeducation and support that are part of good clinical
practice and it should be provided to patients in conjunction with medication management for tics. The
presence of common co-occurring conditions in children and adults with CTDs did not moderate treatment effects, suggesting that CBIT is effective for
reducing tic severity in patients with stable cooccurring conditions.
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